MedTrace Logo

Combined Antidepressant and Behavioural Intervention

NCT05627154 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2024-05-21

No results posted yet for this study

Summary

A body of evidence from both animal and human research suggests that antidepressant drugs may induce early changes in emotional processing that interact with environmental factors to produce a later change in mood. This experimental medicine study will examine the effect of citalopram on emotional cognition under different environmental conditions (as manipulated by the presence or absence of behavioural activation training). Participants will be administered either citalopram or placebo over the course of two weeks. Citalopram will be taken either alone or in combination with behavioural activation training.

Conditions

Interventions

DRUG

Citalopram

Serotonin-reuptake inhibitor commonly used to treat depressive and anxiety disorders.

BEHAVIORAL

Behavioural Activation

A NICE recommended psychological intervention for mild to moderate depression. In behavioural activation, the person with depression and the therapist work together to identify the relationships between the activities the person undertakes and their mood. It encourages people to become less mood-dependent when planning activities and doing constructive things that they would usually avoid doing.

DRUG

Placebo

A lactose-based tablet.

Sponsors & Collaborators

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • University of Oxford

    lead OTHER

Principal Investigators

  • Catherine J Harmer, DPhil · Department of Psychiatry, University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-28
Primary Completion
2023-11-17
Completion
2023-11-17

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05627154 on ClinicalTrials.gov